Display options
Cite
Morsella A, Cadeddu C, Castagna C, et al. "Integrating China in the International Consortium for Personalized Medicine": The Coordination and Support Action to Foster Collaboration in Personalized Medicine Development between Europe and China. Public Health Genomics. 2021;24(5):310-314doi: 10.1159/000516264.
Morsella, A., Cadeddu, C., Castagna, C., Hoxhaj, I., Sassano, M., Wang, C. M., Wang, L., Klessova, S., de Belvis, A. G., Boccia, S., & Ricciardi, W. (2021). "Integrating China in the International Consortium for Personalized Medicine": The Coordination and Support Action to Foster Collaboration in Personalized Medicine Development between Europe and China. Public health genomics, 24(5), 310-314. https://doi.org/10.1159/000516264
Morsella, Alisha, et al. ""Integrating China in the International Consortium for Personalized Medicine": The Coordination and Support Action to Foster Collaboration in Personalized Medicine Development between Europe and China." Public health genomics vol. 24,5 (2021): 310-314. doi: https://doi.org/10.1159/000516264
Morsella A, Cadeddu C, Castagna C, Hoxhaj I, Sassano M, Wang CM, Wang L, Klessova S, de Belvis AG, Boccia S, Ricciardi W. "Integrating China in the International Consortium for Personalized Medicine": The Coordination and Support Action to Foster Collaboration in Personalized Medicine Development between Europe and China. Public Health Genomics. 2021;24(5):310-314. doi: 10.1159/000516264. Epub 2021 Aug 13. PMID: 34392247.
Copy Download .nbib Format: NLM
Share it on

Public Health Genomics. 2021;24(5):310-314. doi: 10.1159/000516264. Epub 2021 Aug 13.

"Integrating China in the International Consortium for Personalized Medicine": The Coordination and Support Action to Foster Collaboration in Personalized Medicine Development between Europe and China.

Public health genomics

Alisha Morsella, Chiara Cadeddu, Carolina Castagna, Ilda Hoxhaj, Michele Sassano, Chiuhui Mary Wang, Lili Wang, Svetlana Klessova, Antonio Giulio de Belvis, Stefania Boccia, Walter Ricciardi

Affiliations

  1. Critical Pathway and Outcome Evaluation Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  2. Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.
  3. Global Partnerships & Projects Fondazione Telethon, Milan, Italy.
  4. BGI Research, Beijing Genomics Institute BGI Group, Beijing, China.
  5. University Côte d'Azur, CNRS, GREDEG, Nice, France.
  6. G.A.C., Innovation Department., G.A.C. Group, Issy-les-Moulineaux, France.
  7. Department of Woman and Child Health and Public Health-Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  8. Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.

PMID: 34392247 DOI: 10.1159/000516264

Abstract

"Integrating China in the International Consortium for Personalized Medicine" (IC2PerMed) is a coordination and support action funded within the Horizon 2020 work program. Following the guidance of the International Consortium for Personalized Medicine (ICPerMed), the project's overarching aim is to align the European Union and China's research agendas in the field of personalized medicine (PM) to enable a swift development of PM approaches in the EU with strong leverage upon EU-Chinese collaboration. Living in the CO-VID-19 era, we are witnessing how the challenges imposed by the pandemic all around the globe have been acting as a catalyst for collaborations and knowledge sharing among national health systems worldwide. Given the strong interest on behalf of both Europe and China in the advancement of PM approaches, now more than ever, a cross-border collaboration between the 2 powers can accelerate the effective translation of such innovation to healthcare systems, advance research, and ensure that such change follows the directions toward the path of sustainability. IC2PerMed developments will be led by European and Chinese experts equally assembled into 3 Working Groups: (1) people and organization, (2) innovation and market, and (3) research and clinical studies in PM. This complex and dynamic network of actions thrives on dialog, cooperation, and alignment of research at national and global levels; work in the direction taken by IC2PerMed shall pave the way toward the realization of PM's full potential, prevent it from becoming a burden for healthcare systems, and, rather, prove that it provides an essential and irreplaceable contribution to their effectiveness, efficiency, and sustainability.

© 2021 The Author(s). Published by S. Karger AG, Basel.

Keywords: China; Genetic/genomic tools; Horizon 2020; Personalized medicine; Public health

Publication Types